Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 17.2% in February

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a large decline in short interest in February. As of February 27th, there was short interest totaling 27,868 shares, a decline of 17.2% from the February 12th total of 33,643 shares. Based on an average trading volume of 52,717 shares, the short-interest ratio is currently 0.5 days. Approximately 2.0% of the shares of the stock are short sold. Approximately 2.0% of the shares of the stock are short sold. Based on an average trading volume of 52,717 shares, the short-interest ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

ADIL has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Wednesday, January 21st. UBS Group set a $8.00 price objective on Adial Pharmaceuticals in a research note on Wednesday, February 11th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Adial Pharmaceuticals has an average rating of “Hold” and an average price target of $22.75.

Institutional Trading of Adial Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its holdings in shares of Adial Pharmaceuticals by 887.3% during the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after buying an additional 109,500 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Adial Pharmaceuticals in the 3rd quarter worth approximately $51,000. Finally, Armistice Capital LLC acquired a new position in shares of Adial Pharmaceuticals in the 4th quarter worth approximately $562,000. 16.41% of the stock is owned by institutional investors.

Adial Pharmaceuticals Stock Performance

ADIL opened at $1.96 on Monday. The firm’s 50-day simple moving average is $3.91 and its 200-day simple moving average is $6.70. Adial Pharmaceuticals has a twelve month low of $1.54 and a twelve month high of $30.25. The firm has a market cap of $2.80 million, a price-to-earnings ratio of -0.10 and a beta of 1.32.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.